PD-1 upregulation is associated with HBV-specific T cell dysfunction in chronic hepatitis B patients. 2008

Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
Key Laboratory of Health Ministry, Institute of Infectious Diseases, First Affiliated Hospital, Medical College, Zhejiang University, 79 Qingchun Road, Hangzhou, Zhejiang 310003, China.

Programmed death-1 (PD-1) is demonstrated to have an increased expression on antigen-specific T cells during chronic virus infections, and the blockage of PD-1/PD-ligand (PD-L1) pathway could restore the function of exhausted T cells. We measured the PD-1 expression levels on HBV-specific CD8 T cells and investigated the role of PD-1/PD-L1 pathway in T-cell responses of patients with different HBV infection statuses. Compared to the patients with convalescent acute hepatitis B, PD-1 expression on total CD8 T cells from chronic hepatitis B (CHB) patients was significantly upregulated, especially on the HBV pentamer-positive CD8 T cells. And PD-L1, but not PD-L2, was also significantly upregulated on PBMC from CHB patients. In CHB patients, HBV-specific T cells and cellular proliferation could be observed under the recombinant HBV-Ag stimulation in vitro, and blockade of PD-1 pathway significantly enhanced the IFN-gamma production and cellular proliferation of PBMC. Furthermore, PD-1 expression level on HBV-pentamers positive CD8 T cells was positively associated with plasma viral load in CHB patients. Thus, PD-1 upregulation on HBV-specific CD8 T cells is engaged in the dysfunction of T cells and high viraemia in CHB patients, and the antiviral T-cell responses could be improved by the blockade of this inhibitory PD-1/PD-L1 pathway.

UI MeSH Term Description Entries
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007963 Leukocytes, Mononuclear Mature LYMPHOCYTES and MONOCYTES transported by the blood to the body's extravascular space. They are morphologically distinguishable from mature granulocytic leukocytes by their large, non-lobed nuclei and lack of coarse, heavily stained cytoplasmic granules. Mononuclear Leukocyte,Mononuclear Leukocytes,PBMC Peripheral Blood Mononuclear Cells,Peripheral Blood Human Mononuclear Cells,Peripheral Blood Mononuclear Cell,Peripheral Blood Mononuclear Cells,Leukocyte, Mononuclear
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D004279 DNA, Viral Deoxyribonucleic acid that makes up the genetic material of viruses. Viral DNA
D005260 Female Females
D006515 Hepatitis B virus The type species of the genus ORTHOHEPADNAVIRUS which causes human HEPATITIS B and is also apparently a causal agent in human HEPATOCELLULAR CARCINOMA. The Dane particle is an intact hepatitis virion, named after its discoverer. Non-infectious spherical and tubular particles are also seen in the serum. Dane Particle,Hepatitis Virus, Homologous Serum,B virus, Hepatitis,Hepatitis B viruses,Particle, Dane,viruses, Hepatitis B
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000998 Antiviral Agents Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral

Related Publications

Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
April 2007, Journal of virology,
Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
September 2010, The Journal of experimental medicine,
Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
September 2008, Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology,
Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
October 2023, Hepatology international,
Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
January 2011, Tropical gastroenterology : official journal of the Digestive Diseases Foundation,
Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
March 2016, Gastroenterology,
Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
June 2009, Journal of hepatology,
Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
May 2009, Zhonghua yi xue za zhi,
Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
February 2020, Scientific reports,
Guoping Peng, and Shuping Li, and Wei Wu, and Xufei Tan, and Yiqiong Chen, and Zhi Chen
June 2004, World journal of gastroenterology,
Copied contents to your clipboard!